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Abstract Tissue factor (TF) is the principal trigger of the
coagulation cascade and involved in arterial thrombus
formation. Platelet-derived growth factor CC (PDGF-CC)
is a recently discovered member of the PDGF family
released upon platelet activation. This study assesses the
impact of PDGF-CC on TF expression in human cells.
PDGF-CC concentration-dependently induced TF expres-
sion by 2.5-fold in THP-1 cells, by 2.0-fold in human
peripheral blood monocytes, by 1.4-fold in vascular smooth
muscle cells, and by 2.6-fold in microvascular endothelial
cells, but did not affect TF expression in aortic endothelial
cells. A similar pattern was observed with PDGF-BB. In
contrast, PDGF-AA did not alter TF expression in THP-1
cells. TF whole cell activity was induced following stimu-
lation with PDGF-BB and PDGF-CC in THP-1 cells.
Real-time polymerase chain reaction revealed that PDGF-
CC induced TF mRNA. PDGF-CC transiently activated
p42/44 MAP kinase [extracellular signal-regulated kinase
(ERK)], while phosphorylation of the MAP kinases c-Jun
NH2-terminal kinase (JNK) and p38 remained unaffected.
PD98059, a specific inhibitor of ERK phosphorylation, but
not the p38 inhibitor SB203580 or the JNK inhibitor
SP600125 prevented PDGF-CC induced TF expression in a
concentration-dependent manner. The effect of PDGF-CC
was antagonized by both PDGF receptor a and PDGF
receptor b neutralizing antibodies; in contrast, PDGF-BB
was only inhibited by PDGF receptor b blocking antibody.
PDGF receptor a and PDGF receptor b inhibition pre-
vented PDGF-CC-induced ERK phosphorylation. PDGF-
CC induces TF expression via activation of a/b receptor
heterodimers and an ERK-dependent signal transduction
pathway.
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Introduction
Platelet-derived growth factor (PDGF) was originally
identified as a mitogen for fibroblasts and vascular smooth
muscle cells and has been linked to a number of human
diseases. The PDGF family consists of at least three
members signaling through the a- and/or b-PDGF receptor
(PDGFR) tyrosine kinases. PDGF-CC, a recently discov-
ered family member, is detectable at a high level in
platelets, vascular smooth muscle cells, and microvascular
endothelial cells [7, 30], and has been characterized as a
potent angiogenic mediator.
Tissue factor (TF), a 47-kDa transmembrane glycopro-
tein, is the main trigger of blood coagulation and plays a
central role in thrombus formation [29]. Various mediators
can induce TF in monocytes, endothelial cells, and vascular
smooth muscle cells [29]. PDGF-BB, a well-characterized
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member of the PDGF family, induces TF expression in
monocytes and vascular smooth muscle cells [6, 18, 25].
However, PDGF-BB constitutes only about 7% of total
PDGF activity in human serum, and the relative contribu-
tion of different PDGF isoforms to thrombus formation and
acute vascular syndromes is unknown [3]. Moreover,
PDGF-CC is released upon platelet activation and can be
cleaved to its active form by plasmin or tissue-type plas-
minogen activator [7, 10, 20], suggesting a possible role at
sites of thrombosis. In spite of these insights, potential
prothrombotic properties of PDGF-CC remain poorly
characterized.
Hence, this study examines the impact of PDGF-CC on
TF expression in human cells.
Materials and methods
Cell culture
Human aortic endothelial cells (HAEC; Clonetics, Alls-
chwil, Switzerland) were cultured as described [11].
Human microvascular endothelial cells (HMVEC; Clone-
tics) were grown in EGM-MV growth medium (Clonetics)
containing 10% FCS, THP-1 cells (LGC Promochem,
Molsheim, France) in RPMI 1640 containing 25 mmol/L
HEPES buffer and 10% FCS, and human aortic vascular
smooth muscle cells (HAVSMC) in DMEM containing
10% FCS. Peripheral blood mononuclear cells were iso-
lated from healthy subjects by density centrifugation in
vacutainer cell preparation tubes with sodium heparin
(Becton-Dickinson, Franklin Lakes, NJ) and further
purified by magnetic-activated cell separation sorting with
anti-human CD14 antibody (Miltenyi Biotec, Cologne,
Germany) conjugated to magnetic beads. Purity was
assessed by flow cytometry (FACSCanto, BD, Heidelberg,
Germany) using FITC-conjugated anti-human CD14 anti-
body (Miltenyi Biotec). Monocytes were cultured in RPMI
1640 containing 25 mmol/L HEPES buffer and 10% FCS.
Human monocytes and THP-1 cells were rendered quies-
cent in starvation medium (0.5% FCS) for 18 and 24 h,
respectively. Adhering cells were grown to confluence in
3 cm dishes and rendered quiescent in starvation medium
for 24 h before stimulation with PDGF-AA, PDGF-BB, or
PDGF-CC (all from R&D, Abingdom, UK) for 5 h.
SB203580 (Sigma, Buchs, Switzerland), PD98059 (Cell
Signaling, Danvers, MA), and SP600125 (Calbiochem,
Nottingham, UK) were added 60 min before stimulation.
Antibodies blocking PDGF receptor a and PDGF receptor
b (MAB 322 and AF 385; R&D Systems, Abingdon, UK)
were added at 5 and 1.25 lg/mL, respectively. Cytotoxicity
was assessed with a colorimetric assay to detect lactate
dehydrogenase release (Roche, Basel, Switzerland) [28].
Western blot
Protein expression was determined by Western blot ana-
lysis as described [27]. Cells were lysed in 50 mmol/L Tris
buffer; 40 lg samples were loaded, separated by 10%
sodium dodecyl sulfate polyacrylamide gel electrophoresis,
and transferred to a polyvinylidene difluoride membrane
(Millipore, Volketswil, Switzerland) by semidry transfer.
Antibodies against human TF (American Diagnostica,
Stamford, CA) were used at 1:2,000 dilution. Antibodies
against phosphorylated p38 MAP kinase (p38), phosphor-
ylated p44/42 MAP kinase [extracellular signal-regulated
kinase (ERK)], and phosphorylated c-Jun NH2-terminal
kinase (JNK; all from Cell Signaling) were used at 1:1,000,
1:5,000, and 1:1,000 dilutions, respectively. Antibodies
against total p38, ERK, and JNK (all from Cell Signaling)
were used at 1:2,000, 1:10,000, and 1:1,000 dilutions,
respectively. All blots were normalized to a-tubulin (aT)
expression (1:20,000 dilution, Sigma) [27].
TF activity
Tissue factor activity was analyzed in THP-1 whole cell
lysates using a colorimetric assay (American Diagnostica).
TF/FVIIa converted factor X to factor Xa, which was
measured by its ability to metabolize a chromogenic sub-
strate. A standard curve with lipidated human TF was
performed to assure that measurements were taken in the
linear range of detection.
Real-time PCR
All real-time PCR experiments were performed in triplicate
using the SYBR Green JumpStart kit (Sigma) in an
MX3000P PCR cycler (Stratagene, Amsterdam, The
Netherlands). Each reaction (25 lL) contained 2 lL
cDNA, 1 pmol of each primer, 0.25 lL of internal refer-
ence dye, and 12.5 lL of JumpStart Taq ReadyMix (con-
taining buffer, dNTPs, stabilizers, SYBR Green, Taq
polymerase, and JumpStart Taq antibody). The following
primers were used: human tissue factor (F3): sense primer:
50-TCCCCAGAGTTCACACCTTACC-30 (bases 508–529
of F3 cDNA; NCBI no. NM 001993), antisense primer:
50-TGACCACAAATACCACAGCTCC-30 (bases 892–913
of F3 cDNA; NCBI no. NM 001993); human L28: sense
primer: 50-GCATCTGCAATGGATGGT-30, antisense pri-
mer: 50-TGTTCTTGCGGATCATGTGT-30. The amplifi-
cation program consisted of 1 cycle at 95C for 10 min
followed by 40 cycles with a denaturing phase at 95C for
30 s, an annealing phase at 60C for 1 min, and an elon-
gation phase at 72C for 1 min. PCR products were ana-
lyzed on an ethidium bromide stained 1% agarose gel, and
a melting curve analysis was performed after amplification
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to verify the accuracy of the amplicon. In each real-time
PCR run for F3 and L28, a calibration curve was included
that was generated from serial dilutions of the respective
purified amplicon [27].
Statistics
Data are presented as mean ± SEM. Statistical analysis
was performed by 2-tailed unpaired Student’s t test or
ANOVA as appropriate. A probability value of\0.05 was
considered significant.
Results
PDGF-CC induces TF protein expression and activity
THP-1 cells were stimulated with PDGF-CC, PDGF-BB,
or PDGF-AA (0.1–10 ng/mL) for 5 h. PDGF-CC induced
TF expression in a concentration-dependent manner with a
maximal effect occurring at 10 ng/mL and resulting in a
2.5-fold induction as compared to unstimulated cells
(n = 9, P \ 0.05; Fig. 1a). Similarly, PDGF-BB enhanced
TF expression by 2.1-fold as compared to control (n = 6,
P \ 0.05; Fig. 1b). In contrast, PDGF-AA did not affect
TF expression (n = 9, P = NS; Fig. 1c). The effect of
PDGF-CC and PDGF-BB on TF protein expression in
THP-1 cells was paralleled by an increased cellular TF
activity 2.0-fold and 1.7-fold, respectively, at the maximal
concentration (n = 4, P \ 0.05; Fig. 1d).
Similar to THP-1 cells, PDGF-CC (1–10 ng/mL)
induced TF expression in human peripheral blood mono-
cytes by 2.1-fold (n = 4, P \ 0.05; Fig. 2a), in human
microvascular endothelial cells by 2.5-fold (n = 11,
P \ 0.05; Fig. 2b), and in human aortic vascular smooth
muscle cells by 1.3-fold (n = 5, P \ 0.05; Fig. 2c). PDGF-
BB (10 ng/mL) induced TF expression in human peripheral
blood monocytes by 1.7-fold (n = 4, P \ 0.05; Fig. 2a), in
microvascular endothelial cells by 1.7-fold (n = 10,
P \ 0.05; Fig. 2b) and in human aortic vascular smooth
muscle cells by 1.4-fold (n = 5, P \ 0.05; Fig. 2c). In
contrast, PDGF-CC and PDGF-BB did not alter TF
expression in human aortic endothelial cells (n = 3,
P = NS; Fig. 2d).
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Fig. 1 PDGF-CC (a) and
PDGF-BB (b), but not PDGF-
AA (c), induced TF protein
expression in THP-1 cells.
Values are indicated as percent
of control and representative of
at least four different
experiments; all blots are
normalized to a-tubulin (aT)
expression; *P \ 0.05 versus
control. d PDGF-BB and
PDGF-CC induced TF whole
cell activity in THP-1 cells;
*P \ 0.05 versus control
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To control for toxic effects, cells were treated with PDGF-
CC, PDGF-BB, or PDGF-AA for 5 h, and cell death was
assessed by LDH release. No significant increase in LDH
release was observed for any cell type and any concentration
of PDGF used (n = 4–15; P = NS; data not shown).
PDGF-CC induces TF mRNA expression
Real-time PCR revealed that PDGF-CC (0.1–10 ng/mL)
induced TF mRNA in THP-1 cells in a concentration-
dependent manner with a maximal effect occurring at
10 ng/mL (3.6–fold vs. control; n = 6, P \ 0.05; Fig. 3).
PDGF-CC induces TF via ERK activation
To assess whether PDGF-CC activates MAP kinases,
THP-1 cells were examined at different time points after
PDGF-CC stimulation. ERK was transiently activated by
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Fig. 2 PDGF-CC-induced TF
protein expression in human
peripheral blood monocytes (a),
human microvascular
endothelial cells (b) and human
aortic vascular smooth muscle
cells (c), but not human aortic
endothelial cells (d). PDGF-BB
is included as a positive control.
Values are indicated as percent
of control and representative of
at least three different
experiments; all blots are
normalized to a-tubulin (aT)
expression; *P \ 0.05 versus
control
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Fig. 3 PDGF-CC induced TF mRNA in THP-1 cells. Values are
indicated as percent of control and representative of six different
experiments; all blots are normalized to L28 mRNA expression;
*P \ 0.05 versus control
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PDGF-CC (10 ng/mL; n = 3, P \ 0.05; Fig. 4a), with
maximal activation after 15 and 30 min. In contrast,
phosphorylation of p38 and JNK remained unaffected as
compared to control (n = 3, P = NS; Fig. 4b, c). Total
expression of ERK, p38, and JNK remained unaltered at all
time points examined (n = 3; Fig. 4). To confirm a role for
ERK activation in PDGF-CC induced TF expression, the
effect of MAP kinase inhibitors on TF induction was
examined. PD98059 (3 9 10-7 to 3 9 10-6 mol/L), a
specific inhibitor of ERK phosphorylation, inhibited
PDGF-CC induced TF expression in a concentration-
dependent manner (n = 6, P \ 0.05; Fig. 5a). In contrast,
SB203580 (10-6 to 10-5 mol/L), an inhibitor of p38
(n = 3, P = NS; Fig. 5b) and SP600125 (10-7 to
10-6 mol/L), an inhibitor of JNK (n = 4, P = NS;
Fig. 5c), did not affect PDGF-CC induced TF expression.
No cytotoxic effect of either of these drugs was observed at
any concentration used (n = 3, P = NS; data not shown).
PDGF-CC induces TF via a/b receptor heterodimer
activation
THP-I cells were pretreated with PDGF receptor blocking
antibodies. The effect of PDGF-BB on TF expression was
inhibited by blockade of PDGF receptor b, but not PDGF
receptor a (n = 3, P = NS; Fig. 6a). The effect of
PDGF-CC on TF expression was inhibited by blockade of
PDGF receptor a (n = 3, P \ 0.05; Fig. 6b) or PDGF
receptor b (n = 3, P \ 0.05; Fig. 6b). No cytotoxic effect
of either of these agents was observed at any concentration
used (n = 3, P = NS; data not shown).
PDGF-CC-induced ERK phosphorylation
depends on PDGFR a/b activation
Transient activation of ERK by PDGF-CC was reversed by
blocking of PDGF receptor a (n = 6, P \ 0.05; Fig. 6c) or
PDGF receptor b (n = 6, P \ 0.05; Fig. 6c).
Discussion
The PDGF family consists of four members, PDGF-A,
PDGF-B, PDGF-C, and PDGF-D [12, 19, 21]. TF, a key
mediator in thrombus formation [29], is induced in
monocytes and vascular smooth muscle cells by PDGF-
BB, a well-characterized member of the PDGF family [6,
18, 25]. PDGF-CC, a newly discovered PDGF isoform, is
secreted upon platelet activation, and latent PDGF-CC
seems to be activated by locally released proteases of the
fibrinolytic and coagulation systems, possibly at the site of
ongoing thrombosis [7, 10, 20]. However, the prothrom-
botic potential of PDGF-CC remains poorly characterized.
Therefore, this study analyzed for the first time the effect of
PDGF-CC on TF expression in human cells. PDGF-CC
induced TF expression in monocytes, microvascular
endothelial cells, and vascular smooth muscle cells with a
maximal response at 10 ng/mL. This effect occurred at the
transcriptional level and was mediated through PDGFR-a/b
heterodimer-dependent ERK phosphorylation.
Monocytes are present throughout atherosclerotic lesion
progression [15, 17]; moreover, monocytes seem to be the
only blood cells capable of synthesizing TF. Hence, the
present findings imply that PDGF-CC may modulate
thrombus formation and propagation by activating mono-
cytes. Since PDGF-CC is mainly secreted by activated
platelets, this effect may be particularly important under
conditions of chronic platelet activation; such conditions
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have been associated with cardiovascular risk factors such
as diabetes mellitus [4], smoking [23] and hyperlipidemia
[1].
The absence of PDGF receptors in endothelial cells
derived from large vessels is well established [2, 22],
whereas microvascular endothelial cells express all PDGF
receptors [16, 22]. In line with this notion, the present study
confirms that PDGF-BB and PDGF-CC do not alter TF
expression in HAECs even at high concentrations. However,
we show that TF expression was concentration-dependently
enhanced in HMVECs upon stimulation with either isoform.
Notably, in contrast to other vascular cells, the effect of
PDGF-CC on TF expression was significantly more potent
as compared to that of PDGF-BB in HMVECs. Considering
that TF is a candidate marker for the progression of micro-
vascular disease in diabetic patients by its association with
microvascular and neurogenic complications [26, 33], and
that diabetes mellitus is associated with chronically
increased platelet activation [4], the present data suggest that
procoagulant activity in patients with ischemic microvas-
cular complications may be triggered by PDGF-CC.
In the vessel wall, TF is constitutively expressed in
subendothelial cells such as VSMCs cells leading to rapid
initiation of coagulation when the vessel is damaged [29].
PDGF-CC induced TF expression in VSMC in a concen-
tration-dependent manner. The rapid and potent induction
of TF by PDGF-CC may be important in those conditions
where VSMCs are exposed to activated platelets such as
during thrombus formation and in those circumstances
where VSMCs migrate such as atherosclerosis and neo-
intimal hyperplasia after vascular intervention [9].
Activated PDGF-CC is a high affinity ligand for
PDGFR-a homodimers, while, in contrast to PDGF-BB, it
fails to activate PDGFR-b homodimers [13]. Similar to
PDGF-BB, PDGF-CC can activate PDGFR-a/b hetero-
dimers in cells expressing both receptor isoforms [13].
To address the importance of a and b PDGF receptors
in PDGF-CC-induced TF expression, isotype-matched
monoclonal blocking Abs directed against a and b PDGF
receptors, respectively, were applied [8]. In THP-1 cells,
PDGFR-b blockade was found to prevent the stimulatory
effects of PDGF-BB and PDGF-CC on TF expression.
PDGFR-a blockade was ineffective in inhibiting PDGF-
BB-induced TF expression, whereas TF expression in
response to PDGF-CC was prevented. However, no stimu-
lation of TF expression was observed after administration
of PDGF-AA, the specific ligand for PDGFR-a/a homo-
dimers. Taken together, these findings indicate an impor-
tant role of PDGFR-a/b signaling in mediating
prothrombotic actions, which has, until now, only been
attributed to the PDGFR-b/b homodimer. Moreover, our
data support the conclusion that PDGFR-a/a homodimer
signaling is not required for the prothrombotic effects of
PDGFs in vascular cells, which supports previously pub-
lished data [12, 14, 19].
MAP kinase activation is a key element in regulating TF
transcription in response to many stimuli [29]. It is well
established that both PDGF-BB induced chemotaxis and
TF induction depend on activation of ERK [5, 18, 31, 32].
In the present study, rapid and transient activation of ERK
was observed after stimulation by PDGF-CC, whereas JNK
and p38 were not affected. Consistent with MAP kinase
activation, the increase in TF protein expression by PDGF-
CC was preceded by an enhanced TF mRNA expression.
Inhibition of MAP kinases by specific inhibitors confirmed
that PDCF-CC-induced TF expression was strictly ERK-
dependent; moreover, PDGFR-a and PDGFR-b blockade
prevented PDGF-CC-induced ERK phosphorylation, which
is consistent with PDGFR-a/b-dependent signaling. In line
with this notion, previous studies have described that the
downstream signaling profile of PDGFR-b is largely ERK-
dependent [24], whereas the PDGFR-a/a homodimer may
also be able to induce JNK in several cell lines [24].
In conclusion, these data represent the first evidence that
PDGF-CC, a newly discovered member of the PDGF family,
exerts prothrombotic actions via PDGFR-a/b signaling
resulting in ERK-dependent induction of TF expression and
activity. The ability of PDGF-CC to stimulate TF expression
not only in monocytes, but also in microvascular endothelial
cells suggests that it is involved in thrombotic microvascular
complications. Hence, a better understanding of the action of
PDGF-CC may help refine strategies to prevent microvas-
cular dysfunction. Further, PDGF-CC may be relevant for
VSMC migration in conditions such as neointimal hyper-
plasia after vascular intervention.
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